About
NYBC Ventures is a $50 million venture fund committed to fostering innovation in blood-related and cellular medicines and technologies. With a strategic focus on therapeutics, medical devices, and cutting-edge technologies, NYBC Ventures aims to tackle pressing challenges in benign hematology, infectious diseases, and transfusion medicine. By partnering with visionary entrepreneurs and groundbreaking startups, the fund seeks to accelerate the development of transformative solutions that can significantly enhance patient care and outcomes in the hematology space. Through its investments, NYBC Ventures is not only driving financial returns but also contributing to the advancement of healthcare solutions that can improve the quality of life for patients worldwide.